This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rini, B. I. Search for Related Content PubMed PubMed Citation Articles by Rini, B. I. Related Collections Clinical Research Clinical Research: Clinical Trials

Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions

Author's Affiliation: Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Requests for reprints: Brian I. Rini, Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195. Phone: 216-444-9567; Fax: 216-636-0636; E-mail: rinib2{at}ccf.org.

Renal cell carcinoma is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF). Recently, VEGF-targeted therapies have been identified as a promising therapeutic approach. Three agents targeting the VEGF pathway have shown clinical activity as monotherapy in metastatic renal cell carcinoma: the anti-VEGF monoclonal antibody, bevacizumab, and small-molecule VEGF receptor tyrosine kinase inhibitors, sorafenib and sunitinib. This article explores these agents in terms of their mechanisms of action, clinical efficacy, and toxicity profiles. This article also reviews future development strategies, including combination regimens and drug sequencing, trial design considerations, and patient selection opportunities.

This article has been cited by other articles:

				E J Chung, S Yoo, H J Lim, S H Byeon, J H Lee, and H J Koh Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib Br. J. Ophthalmol., July 1, 2009; 93(7): 958 - 963. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib Clin. Cancer Res., January 15, 2009; 15(2): 578 - 588. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]

				H. M.W. Verheul, B. Salumbides, K. Van Erp, H. Hammers, D. Z. Qian, T. Sanni, P. Atadja, and R. Pili Combination Strategy Targeting the Hypoxia Inducible Factor-1{alpha} with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors Clin. Cancer Res., June 1, 2008; 14(11): 3589 - 3597. [Abstract] [Full Text] [PDF]

				L. Moreno-Vinasco, M. Gomberg-Maitland, M. L. Maitland, A. A. Desai, P. A. Singleton, S. Sammani, L. Sam, Y. Liu, A. N. Husain, R. M. Lang, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension Physiol Genomics, April 1, 2008; 33(2): 278 - 291. [Abstract] [Full Text] [PDF]